> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# DiA Imaging’s AI Imaging Software Cleared
- URL: https://www.fdaweb.com/dia-imagings-ai-imaging-software-cleared/
- Published: 2023-02-08T12:00:00.000Z
- Updated: 2026-09-14T18:15:06.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5153735

FDA has cleared a [DiA Imaging Analysis](https://www.dia-analysis.com/?ref=fdaweb.com) 510(k) for its LVivo IQS, a new artificial intelligence-based vendor-neutral software that the company says enables ultrasound users to acquire high-quality, interpretable cardiac images that can be used to make better clinical heart assessments.

The company says high-quality cardiac ultrasound imaging is difficult because of the constant beating of the heart and its deep location in the chest. “DiA’s new [LVivo IQS - Image Quality Score](https://www.dia-analysis.com/lvivo-iqs?ref=fdaweb.com) provides real-time image quality feedback while scanning the left ventricle of the heart to assess the heart’s performance,” it says, adding that the software uses colors and numerical scoring to tag an image’s quality level as it is being scanned, which helps users to produce “optimal interpretable images.”

The clearance relied on data from a clinical study that demonstrated “high agreement between the LVivo IQS AI’s quality score feedback and the ability to obtain clinically interpretable images as evaluated by cardiologists specializing in echocardiography,” the company says, adding that 91% of images saved by point-of-care residents using LVivo IQS, were found to be clinically interpretable images.